Patent Document ID: 9886553
Application ID: 13787137
Patent Flag: 1

Claim One:
1. A method for evaluating the risk of a major adverse cardiac event (MACE) for a subject within one year and hospitalizing the subject, the method comprising: (a) determining a first level of soluble ST2 in a biological sample comprising serum, blood, or plasma that is obtained from a subject at a first time point (ST2 T0) using an immunoassay comprising a monoclonal antibody that binds specifically to ST2; (b) determining a second level of soluble ST2 in a biological sample comprising serum, blood, or plasma that is obtained from the subject at a second time point (ST2 T1) using the immunoassay comprising the monoclonal antibody that specifically binds to ST2; (c) determining a level of a natriuretic peptide (NP) in a biological sample comprising serum, blood, or plasma that is obtained from the subject at the second time point (NP T1) using an immunoassay comprising a monoclonal antibody that specifically binds to the NP; (d) determining a MACE risk score (MACERS) for a subject utilizing, at least in part, the ratio of ST2 T1 to ST2 T0, in combination with a weighted logarithm of NP T1; (e) identifying a subject having an elevated MACERS as compared to a reference MACERS as having an increased risk of a MACE within one year; and (f) hospitalizing the subject identified as having an increased risk of a MACE within one year.